PDF(Pubmed)
Abstract：
UNASSIGNED: Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) after total knee arthroplasty (TKA) is rare.
UNASSIGNED: The literature that analyses the cutaneous manifestations of PCDLBCL and assesses the effect and the outcome of treatment is scarce.
UNASSIGNED: We described a case of PCDLBCL after TKA, whose cutaneous mass develops around surgical sites, mimicking a prosthetic joint infection. In addition, we conducted a systematic review of 29 reported cases with PCDLBCL. Primary endpoint for the review was main cutaneous manifestations of PCDLBCL. Secondary endpoint included treatment options of PCDLBCL and optimal therapeutic method.
UNASSIGNED: We found that the main cutaneous manifestations include infiltrative cutaneous lesions such as macules, papules or nodules, some of them presented as ulcerations or formation of vesicles, subcutaneous nodules or both. The treatment options include excision, radiotherapy, chemotherapy, and even \"watchful waiting\" as spontaneous regression was noted in some cases. Systemic chemotherapy is the most frequent initial treatment approach chosen, of which rituximab is often combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy and patients who received systemic rituximab tend to have a better overall survival (OS) time than those who did not.
UNASSIGNED: PCDLBCL is a rare disease after TKA, however, an early recognition and distinguishing from infection is still needed. Patients with PCDLBCL may profit from rituximab-based chemotherapy, increasing the survival rate, despite the high relapse rate and limited OS time in some cases.
UNASSIGNED: The literature that analyses the cutaneous manifestations of PCDLBCL and assesses the effect and the outcome of treatment is scarce.
UNASSIGNED: We described a case of PCDLBCL after TKA, whose cutaneous mass develops around surgical sites, mimicking a prosthetic joint infection. In addition, we conducted a systematic review of 29 reported cases with PCDLBCL. Primary endpoint for the review was main cutaneous manifestations of PCDLBCL. Secondary endpoint included treatment options of PCDLBCL and optimal therapeutic method.
UNASSIGNED: We found that the main cutaneous manifestations include infiltrative cutaneous lesions such as macules, papules or nodules, some of them presented as ulcerations or formation of vesicles, subcutaneous nodules or both. The treatment options include excision, radiotherapy, chemotherapy, and even \"watchful waiting\" as spontaneous regression was noted in some cases. Systemic chemotherapy is the most frequent initial treatment approach chosen, of which rituximab is often combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy and patients who received systemic rituximab tend to have a better overall survival (OS) time than those who did not.
UNASSIGNED: PCDLBCL is a rare disease after TKA, however, an early recognition and distinguishing from infection is still needed. Patients with PCDLBCL may profit from rituximab-based chemotherapy, increasing the survival rate, despite the high relapse rate and limited OS time in some cases.
摘要：
■全膝关节置换术（TKA）后原发性皮肤弥漫性大B细胞淋巴瘤（PCDLBCL）很少见。
■分析PCDLBCL的皮肤表现并评估治疗效果和结果的文献很少。
■我们描述了TKA后PCDLBCL的一例，其皮肤肿块在手术部位周围发展，模仿假肢关节感染。此外,我们对29例报告的PCDLBCL病例进行了系统评价.该综述的主要终点是PCDLBCL的主要皮肤表现。次要终点包括PCDLBCL的治疗选择和最佳治疗方法。
■我们发现主要的皮肤表现包括浸润性皮肤病变，如斑疹，丘疹或结节，其中一些表现为溃疡或形成囊泡，皮下结节或两者兼有。治疗方案包括切除,放射治疗,化疗,在某些情况下，甚至注意到“警惕等待”作为自发回归。全身化疗是最常见的初始治疗方法，其中利妥昔单抗通常与环磷酰胺联合使用，阿霉素,长春新碱,和泼尼松(CHOP)化疗,接受全身性利妥昔单抗的患者的总生存期(OS)时间往往优于未接受全身性利妥昔单抗的患者.
■PCDLBCL是TKA后的一种罕见疾病，然而,仍然需要早期识别和区分感染。PCDLBCL患者可能受益于以利妥昔单抗为基础的化疗，提高存活率，尽管在某些情况下复发率高，OS时间有限。
■分析PCDLBCL的皮肤表现并评估治疗效果和结果的文献很少。
■我们描述了TKA后PCDLBCL的一例，其皮肤肿块在手术部位周围发展，模仿假肢关节感染。此外,我们对29例报告的PCDLBCL病例进行了系统评价.该综述的主要终点是PCDLBCL的主要皮肤表现。次要终点包括PCDLBCL的治疗选择和最佳治疗方法。
■我们发现主要的皮肤表现包括浸润性皮肤病变，如斑疹，丘疹或结节，其中一些表现为溃疡或形成囊泡，皮下结节或两者兼有。治疗方案包括切除,放射治疗,化疗,在某些情况下，甚至注意到“警惕等待”作为自发回归。全身化疗是最常见的初始治疗方法，其中利妥昔单抗通常与环磷酰胺联合使用，阿霉素,长春新碱,和泼尼松(CHOP)化疗,接受全身性利妥昔单抗的患者的总生存期(OS)时间往往优于未接受全身性利妥昔单抗的患者.
■PCDLBCL是TKA后的一种罕见疾病，然而,仍然需要早期识别和区分感染。PCDLBCL患者可能受益于以利妥昔单抗为基础的化疗，提高存活率，尽管在某些情况下复发率高，OS时间有限。
